Treatment of Localized Non-Hodgkin's Lymphoma: Comparison of Chemotherapy (CHOP) to Chemo-therapy Plus Radiation Therapy

Association of Patient Demographic Characteristics and Insurance Status with Survival in Cancer Randomized Clinical Trials with Positive Findings

JM Unger;CD Blanke;M Leblanc;W Barlow;R Vaidya;M Fleury;SD Ramsey;DL Hershman JAMA Network Open Apr 1;3(4):e203842

PMid: PMID32352530 | PMC number: PMC7193331

Association between body mass index and cancer survival in a pooled analysis of 22 clinical trials

H Greenlee;J Unger;M Leblanc;S Ramsey;D Hershman Cancer Epidemiology Biomarkers & Prevention 2017 Jan;26(1):21-29; 2016 Dec 16. [Epub ahead of print]

PMid: PMID27986655 | PMC number: PMC5370550

The effect of positive SWOG treatment trials on survival of patients with cancer in the US population

JM Unger;M Leblanc;CD Blanke JAMA Oncology Oct 1;3(10):1345-1351

PMid: PMID28586789; PMC5710507

The impact of positive SWOG treatment trials on population survival

J Unger;M LeBlanc;C Blanke J Clin Oncol 35, 2017 (suppl; abstr 6513); American Society of Clinical Oncology Annual Meeting (June 2-6, 2017, Chicago, IL), poster discussion

Continued risk of relapse independent of treatment modality in limited stage diffuse large B-cell lymphoma: Final and long-term analysis of SWOG Study S8736

D Stephens;M Leblanc;H Li;S Puvvada;D Persky;J Friedberg;S Smith Journal of Clinical Oncology, Sep 1;34(25):2997-3004; 2016 Jul 5 [Epub ahead of print]

PMid: PMID27382104 | PMC number: PMC5012710

Chemotherapy + radiation and chemotherapy alone in limited stage diffuse large B-cell lymphoma (DLBCL): Final and long-term analysis of SWOG Study S8736 (http://onlinelibrary.wiley.com/doi/10.1002/hon.2227/epdf)

DM Stephens;M Leblanc;H Li;TP Miller;S Puvvada;D Persky;JW Friedberg;S Smith Hematological Oncology 33: (Suppl S1, abst. 128) p.170; International Conference on Malignant Lymphoma (June 17-20, 2015, Lugano, Switzerland), oral;

Genetic polymorphisms in oxidative stress-related genes are associated with outcomes following treatment for aggressive B-cell non-Hodgkin lymphoma

H Gustafson (Tardif);S Yao;B Goldman;K Lee;C Spier;M LeBlanc;L Rimsza;JR Cernan;TM Habermann;BK Link;MJ Mauer;SL Slager;D Persky;T Miller;RI Fisher;C Ambrosone;M Briehl American Journal of Hematology 89(6):639-645;

PMid: PMID24633940 | PMC number: PMC4137041

Association between BMI at treatment initiation and cancer survival across multiple SWOG trials

H Greenlee;J Unger;M Leblanc;D Hershman AACR Research International Conference on Frontiers on Cancer Research Prevention (Sept 28-Oct 1, 2014, New Orleans, LA; poster

Non-hodgkins lymphoma

R Fisher;P Mauch;J Friedberg;L Rimsza In Cancer: Principles and Practice of Oncology, 8th edition, Lippincott, Williams & Wilkins, Baltimore, MD, pp 2098-2158, 2008

The Southwest Oncology Group: progress in cancer research [PMID18929152]

CA Coltman Seminars in Oncology 35(5):545-552

Diffuse aggressive histologies of non-Hodgkin lymphoma: treatment and biology of limited disease

TP Miller;CM Spier;L Rimsza Seminars in Hematology 43:207-212

Histologic subtypes do not confer unique outcomes in early-stage lymphoma: long-term follow-up of SWOG 8736

CM Spier;M LeBlanc;EM Chase;RI Fisher;TP Miller Blood 104(11): #3263

CHOP alone compared to CHOP plus radiotherapy for early stage aggressive non-Hodgkins lymphomas: update of the Southwest Oncology Group (SWOG) randomized trial.

TP Miller;M LeBlanc;C Spier;E Chase;RI Fischer Blood 98(11):724a-725a(#3024)

Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high grade non-hodgkin's lymphoma.

TP Miller;S Dahlberg;JR Cassady;DJ Adelstein;CM Spier;TM Grogan;M LeBlanc;S Carlin;E Chase;RI Fisher New England Journal of Medicine 339:21-26

Treatment of early stage intermediate and high grade lymphomas.

TP Miller;M LeBlanc;RI Fisher Annals of Hematology 77(Suppl.1):A18(#69)

CHOP plus radiotherapy is superior to CHOP alone for adjuvant therapy of resected localized unfavorable non-Hodgkin's lymphoma: A Southwest Oncology Group study.

TP Miller;S Dahlberg;JR Cassady;DJ Edelstein;CM Spier;TM Grogan;S Carlin;E Chase;M LeBlanc;RI Fisher Adjuvant Therapy of Cancer VIII, SE Salmon eds Lipp-Raven 27:245-250

Three cycles of CHOP (3) plus radiotherapy (RT) is superior to eight cycles of CHOP (8) alone for localized intermediate and high grade non-Hodgkin's lymphoma (NHL): A Southwest Oncology Group study.

TP Miller;S Dahlberg;JR Cassady;C Spier;TM Grogan;S Carlin;E Chase;RI Fisher American Society of Clinical Oncology 15:411(#1257)

CHOP plus radiotherapy (RT) is superior to CHOP alone for adjuvant therapy of resected localized unfavorable non-Hodgkin's lymphoma (NHL).

TP Miller;S Dahlberg;JR Cassady;C Spier;TM Grogan;S Carlin;E Chase;RI Fisher Proc 8th Intl Conf on the Adjuvant Therapy of Cancer :47(#27)

Superiority of a brief course of CHOP plus radiotherapy (RT) over CHOP alone in localized unfavorable non-Hodgkin's lymphoma (NHL) is seen in lowest risk subgroups: A Southwest Oncology Group study.

TP Miller;S Dahlberg;JR Cassady;C Spier;TM Grogan;S Carlin;E Chase;RI Fisher Annals of Oncology 7(3):23(#076)